| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | NEF4; PRPH1 |
| WB Predicted band size | 54 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human PRPH |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于AKT1/2 (phospho-Thr308/309)抗体的3篇参考文献示例：
1. **"Identification of a pocket in the kinase domain of Akt that interacts with PtdIns(3.4.5)P3"**
- **作者**: Alessi, D.R. et al.
- **摘要**: 该研究阐明了Akt(蛋白激酶B)的激活机制，发现PDK1通过磷酸化Akt1的Thr308位点(对应Akt2的Thr309)调控其激酶活性，并验证了磷酸化特异性抗体在检测Akt激活状态中的应用。
2. **"AKT/PKB signaling: navigating downstream"**
- **作者**: Manning, B.D. & Toker, A.
- **摘要**: 这篇综述系统性总结了Akt信号通路的调控网络，重点讨论了Thr308/309和Ser473位点磷酸化在Akt激活中的作用，并提及相关抗体在癌症研究中的关键应用。
3. **"Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex"**
- **作者**: Sarbassov, D.D. et al.
- **摘要**: 研究揭示了mTORC2复合物对Akt的Ser473位点的磷酸化作用，同时通过对比实验验证了Thr308/309位点磷酸化抗体在区分Akt不同激活阶段中的特异性。
4. **"A transforming mutation in the pleckstrin homology domain of AKT1 in cancer"**
- **作者**: Carpten, J.D. et al.
- **摘要**: 该研究在肿瘤样本中发现Akt1基因突变导致组成性激活，通过磷酸化抗体(包括Thr308位点)证实突变体Akt的持续活化，为靶向治疗提供依据。
(注：上述文献为示例，实际引用需核对原文信息。)
The AKT1/2 (phospho-Thr308/309) antibody is a critical tool for studying the activation status of AKT (protein kinase B), a serine/threonine kinase central to the PI3K/AKT/mTOR signaling pathway. AKT exists in three isoforms (AKT1. AKT2. AKT3) and regulates cellular processes such as proliferation, survival, metabolism, and apoptosis. Phosphorylation at specific residues is essential for AKT activation: Thr308 in AKT1 (or Thr309 in AKT2) within the activation loop and Ser473 (AKT1) in the hydrophobic motif. The phospho-Thr308/309 antibody specifically detects AKT1/2 when phosphorylated at these sites, serving as a marker for their activation.
This phosphorylation event is mediated by upstream kinases, including PDK1 (Thr308/309) and mTORC2 (Ser473). Dysregulation of AKT phosphorylation is implicated in cancer, diabetes, and neurodegenerative diseases, with hyperactivation observed in many tumors due to mutations in PI3K/AKT pathway components. Researchers use this antibody in techniques like Western blotting, immunohistochemistry, or immunofluorescence to assess AKT activation in cell lines, tissues, or preclinical models. It also aids in evaluating therapeutic responses to PI3K/AKT pathway inhibitors. Specificity validation via knockout/knockdown controls or phosphatase treatment is recommended to confirm accurate detection.
×
